Current Takeaway
Wirth and Steinacker (2025) propose that insufficient activity of the sodium-potassium pump (Na-K-ATPase) in skeletal muscle cells may underlie the severe muscle weakness, twitching, and cramps seen in the most severely ill ME/CFS patients. The proposed mechanism is a self-reinforcing cycle: pump failure leads to membrane depolarisation, intracellular sodium and calcium overload, mitochondrial damage, reduced ATP availability, and further pump impairment.
This is still an early hypothesis rather than a validated treatment pathway. No clinical trial has shown that directly modulating Na-K-ATPase activity improves ME/CFS symptoms. It belongs in treatments because the model makes the pump, upstream pump inhibitors, and sarcolemmal ion handling concrete therapeutic targets.
Why This Matters
Severe muscle weakness and fasciculations are among the most disabling symptoms in very severe ME/CFS, yet standard neurological investigation often fails to identify a neuronal explanation. A muscle-cell-intrinsic model grounded in ion transport and electrophysiology shifts attention toward measurable pump activity, intracellular sodium-calcium handling, mitochondrial protection, and interventions that might stabilise muscle membrane excitability.
The thread also connects to Wirth and Scheibenbogen’s broader work on acquired ischemic mitochondrial myopathy, where impaired perfusion and cellular energy failure can converge on sodium-calcium overload in skeletal muscle. A related Scheibenbogen patent on soluble guanylate cyclase stimulation sits closer to the vascular-perfusion side of the model, but it is relevant because improved perfusion could theoretically reduce downstream ion-pump stress.
State of Evidence
- Established: Severe skeletal muscle symptoms, including weakness, twitching, and cramps, are recognised in very severe ME/CFS. Sodium overload and skeletal muscle energy failure are recurring themes in ME/CFS and Long COVID mechanism papers.
- Plausible but early: Na-K-ATPase hypofunction could explain concurrent impaired contraction and muscle hyperexcitability. Autoantibodies, mitochondrial dysfunction, oxidative stress, hormonal deficits, and impaired perfusion could theoretically converge on pump inhibition or inadequate ATP supply for pump function.
- Not established: Whether Na-K-ATPase activity is reduced in ME/CFS skeletal muscle. Whether pump dysfunction is causal, secondary, or a downstream endpoint of vascular and mitochondrial pathology. Whether any existing pump-modulating intervention is safe or effective in ME/CFS.
- Key limitations: The central source is a hypothesis paper and literature synthesis, not an experimental patient study. Direct validation would likely require invasive or burdensome skeletal muscle measurements in a severely ill population.
Timeline
2024-11-06 - Wirth and Scheibenbogen consolidate acquired ischemic mitochondrial myopathy model
Scheibenbogen and Wirth proposed a model in which impaired skeletal muscle blood flow and energy production create an acquired ischemic mitochondrial myopathy. In this framing, low perfusion and ATP shortage can produce sodium-calcium overload, mitochondrial damage, and persistent exertional muscle failure. This does not prove Na-K-ATPase dysfunction as the initiating lesion, but it gives the pump hypothesis a broader vascular-metabolic context.
Sources:
2025-09-26 - Hypothesis paper proposes Na-K-ATPase dysfunction as the cellular basis of muscle weakness and fasciculations in severe ME/CFS
Wirth and Steinacker (Mitodicure GmbH / Ulm University) published a hypothesis paper and literature synthesis on Preprints.org arguing that insufficient sodium-potassium pump activity explains the constellation of skeletal muscle symptoms — myasthenia, fasciculations, and cramps — seen in severely ill, bedridden ME/CFS patients. The central claim is that Na-K-ATPase hypofunction causes progressive membrane depolarisation that simultaneously makes muscle fibres hyperexcitable, producing involuntary twitching, and impairs effective contraction, producing weakness.
Depolarisation drives intracellular sodium accumulation, which is accompanied by calcium overload. The calcium overload damages mitochondria, reduces ATP output, increases reactive oxygen species production, and further inhibits the pump, creating a self-reinforcing cycle. The authors connect this model to several upstream factors already documented in ME/CFS research: GPCR autoantibodies and other autoantibody classes that can inhibit ion transporters, primary mitochondrial dysfunction independent of sodium cycling, hormonal deficits including thyroid and sex hormones that normally stimulate pump expression, and oxidative stress during post-exertional malaise.
The practical implication, if the hypothesis holds, is that Na-K-ATPase becomes a concrete therapeutic target rather than an incidental finding. The paper does not present original experimental data; validation would require direct electrophysiological and ionic measurement in biopsy samples from severely affected patients.
Sources:
2025-12-25 - Scheibenbogen patent targets vascular dysfunction with soluble guanylate cyclase stimulation
Scheibenbogen and collaborators filed a patent around treating chronic vascular dysfunction using soluble guanylate cyclase stimulation. This is not a Na-K-ATPase patent and should not be treated as direct evidence for pump-targeting therapy. It is relevant as an adjacent treatment direction because improving microvascular perfusion and nitric-oxide-like signalling could theoretically reduce tissue hypoxia, mitochondrial stress, and downstream ion-pump failure.
Sources:
Open Questions
- Can Na-K-ATPase activity be measured non-invasively or with low-burden sampling in severe ME/CFS?
- Which upstream factor contributes most to pump impairment: autoantibodies, mitochondrial ATP shortage, oxidative stress, hormonal signalling, or low perfusion?
- Is the proposed chronic depolarised state specific to very severe disease, or is it a severe endpoint of mechanisms also active during post-exertional malaise in milder patients?
- Are there plausible pump-stabilising, perfusion-improving, or mitochondrial-protective interventions that are safe enough to test in this population?